Literature DB >> 14226130

CLINICAL EVALUATION OF VINCRISTINE (NSC-67574).

R K SHAW, J A BRUNER.   

Abstract

Entities:  

Keywords:  ANTINEOPLASTIC AGENTS; DRUG THERAPY; NEOPLASM THERAPY; TOXICOLOGIC REPORT; VINCRISTINE

Mesh：

Substances：

Year:  1964        PMID： 14226130

Source DB:  PubMed          Journal:  Cancer Chemother Rep        ISSN： 0069-0112


× No keyword cloud information.
  6 in total

Review 1.  Chemotherapy in colorectal cancer.

Authors:  T J McElwain
Journal:  Proc R Soc Med       Date:  1973-12

2.  Death from paralytic ileus following vincristine therapy.

Authors:  P J Toghill; J D Burke
Journal:  Postgrad Med J       Date:  1970-05       Impact factor: 2.401

3.  Can severe vincristine neurotoxicity be prevented?

Authors:  Z R Desai; H W Van den Berg; J M Bridges; R G Shanks
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

4.  The pharmacokinetics of vincristine in man: reduced drug clearance associated with raised serum alkaline phosphatase and dose-limited elimination.

Authors:  H W Van den Berg; Z R Desai; R Wilson; G Kennedy; J M Bridges; R G Shanks
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

5.  High incidence of vincristine-induced neuropathy in lymphomas.

Authors:  S M Watkins; J P Griffin
Journal:  Br Med J       Date:  1978-03-11

6.  Treatment of metastatic testicular tumours with bleomycin, etoposide, cisplatin and vincristine (BEPV).

Authors:  B A Price; N H Peters
Journal:  J R Soc Med       Date:  1992-11       Impact factor: 18.000
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.